Influenza A Ag Rapid Test Device

Influenza A is one of the major types of influenza virus responsible for seasonal flu outbreaks and wider respiratory infection activity. Influenza symptoms may include fever, cough, sore throat, runny nose, body aches, headache, fatigue, and chills.

• Rapid flu testing is important during seasonal outbreaks because early identification can help guide treatment decisions.
• The Influenza A Ag Rapid Test Device may help support infection-control practices and patient management.
• Influenza A symptoms can overlap with Influenza B, COVID-19, RSV, and common cold infections.
• Rapid antigen screening supports hospitals, clinics, emergency departments, laboratories, public health programs, and point-of-care settings.

The Influenza A Ag Rapid Test Device by LARKSOIS Pharma may be used in professional diagnostic and respiratory infection screening environments.

Applications

• Hospitals and clinics
• Emergency departments
• Diagnostic laboratories
• Fever clinics
• Respiratory infection screening programs
• School, workplace, and travel-related health screening
• Public health outbreak support
• Professional point-of-care testing
• International diagnostic distribution

• The Influenza A Ag Rapid Test Device works on lateral flow immunochromatographic assay technology.
• After the nasal or nasopharyngeal swab sample is collected and mixed with extraction buffer, the prepared specimen is added to the test device.
• If Influenza A antigen is present at or above the detection level, it reacts with specific antibodies on the test strip and produces a visible test line.
• A control line confirms that the test procedure has worked correctly.

The Influenza A Ag Rapid Test Device uses rapid lateral flow immunochromatographic technology for qualitative detection of Influenza A antigen in nasal or nasopharyngeal swab specimens.

Benefits

• Rapid visual result
• Detects Influenza A antigen
• Uses nasal or nasopharyngeal swab specimens
• No complex instrument required
• Suitable for professional point-of-care testing
• Helps support early flu screening
• Useful during seasonal respiratory outbreaks
• Professional infectious disease diagnostic application

The Influenza A Ag Rapid Test Device supports nasopharyngeal swab and nasal swab specimens. Proper sample collection is important because test performance depends strongly on sample quality, symptom timing, and correct procedure.

Guidance

• Use approved nasal or nasopharyngeal swab specimens only
• Collect specimens according to the product insert
• Use clean and suitable swab collection materials
• Avoid contaminated or improperly collected samples
• Mix the swab sample with extraction buffer as instructed
• Apply the prepared specimen correctly to the test device
• Read results only within the recommended time window
• Handle all respiratory specimens according to laboratory safety procedures

Note

Specimen collection, extraction, testing, timing, and storage should always follow the official LARKSOIS Pharma kit insert.

The Influenza A Ag Rapid Test Device by LARKSOIS Pharma is designed for qualitative detection of Influenza A antigen in nasal or nasopharyngeal swab specimens. The listed cut-off is 100 TCID/ml, and results should be interpreted with clinical findings and local influenza activity.

• A positive result means Influenza A antigen has been detected.
• Rapid detection can support timely clinical decisions and infection-control measures.
• A negative result does not always rule out influenza, especially if symptoms continue or sample quality is poor.
• If clinical suspicion remains high, molecular testing such as PCR may be recommended.

Rapid influenza antigen tests are useful for fast screening, but molecular tests are generally more accurate. The Influenza A Ag Rapid Test Device should be used as a professional screening aid, not as the only basis for final clinical decisions.

Instructions

• For professional in-vitro diagnostic use only
• Use approved nasal or nasopharyngeal swab specimens only
• Incorrect specimen collection may affect results
• False positive or false negative results may occur
• Negative results may need confirmation if symptoms strongly suggest flu
• Molecular testing may be recommended when clinical suspicion remains high
• Read results only within the recommended time
• Follow the official product insert carefully

Instructions

• Rapid visual result
• Detects Influenza A antigen
• Uses nasal or nasopharyngeal swab specimens
• No complex instrument required
• Suitable for professional point-of-care testing
• Helps support early flu screening
• Useful during seasonal respiratory outbreaks
• International-quality diagnostic product from LARKSOIS Pharma

Note

The Influenza A Ag Rapid Test Device by LARKSOIS Pharma is designed for practical use, rapid screening, and international diagnostic supply requirements.

Steps

• Bring the test device, swab specimen, and extraction buffer to room temperature
• Collect the nasal or nasopharyngeal swab specimen according to instructions
• Place the swab into the extraction buffer tube
• Mix the sample properly as instructed in the product insert
• Remove the test cassette from the sealed pouch
• Apply the prepared specimen to the sample well
• Wait for the recommended reaction time
• Read the test and control lines within the valid time window
• Dispose of used materials according to laboratory safety procedures

Note

Testing should be performed by trained healthcare professionals according to the official LARKSOIS Pharma product insert.

Positive

A positive result means Influenza A antigen has been detected. The result should be interpreted with symptoms, clinical history, and local influenza activity.

Negative

A negative result means Influenza A antigen was not detected at the test’s detectable level. If symptoms continue or clinical suspicion remains high, molecular testing such as PCR may be recommended.

Invalid

If the control line does not appear, the test is invalid. Repeat testing with a fresh device is required.

Instructions

• Store the Influenza A Ag Rapid Test Device according to the product label and insert
• Store in a cool and dry place
• Keep sealed until use
• Protect from heat, sunlight, and moisture
• Do not freeze unless specified
• Do not use expired kits
• Use immediately after opening the pouch
• Follow all instructions for use carefully

Instructions

• For professional in-vitro diagnostic use only
• Handle respiratory specimens carefully
• Wear gloves and appropriate protective equipment during testing
• Do not reuse the test cassette
• Avoid specimen contamination
• Do not use damaged or expired kits
• Read results only within the recommended time
• Confirm results with clinical evaluation when required

LARKSOIS Pharma provides diagnostic solutions for hospitals, laboratories, clinics, distributors, healthcare procurement agencies, and public health programs. The Influenza A Ag Rapid Test Device is designed for practical use, rapid screening, and international diagnostic supply requirements.

Advantages

• International infectious disease rapid test portfolio
• Reliable respiratory infection screening support
• Suitable for hospitals, clinics, and laboratories
• Distributor-friendly product support
• Professional healthcare quality standards
• Practical point-of-care diagnostic format
• Accessible Influenza A antigen screening solution